Evidence map›Paper›PMID 41939011›Full record

ArticleThe Lancet regional health. Europe2026

Socioeconomic disparities in treatment and survival of oesophageal and gastric cancer in the Netherlands: a nationwide population-based study.

Dillen C van der Aa, Mats D Teeken, Hanneke W M van Laarhoven, Suzanne S Gisbertz, Sjoerd M Lagarde, Nadia Haj Mohammad, Peter S N van Rossum, Rob H A Verhoeven, Mark I van Berge Henegouwen

Abstract read
In one paragraph

Article in The Lancet regional health. Europe, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Dillen C van der AaDepartment of Surgery, Amsterdam UMC, Location University of Amsterdam, Meibergdreef 9, Amsterdam, the Netherlands.
Mats D TeekenDepartment of Surgery, Amsterdam UMC, Location University of Amsterdam, Meibergdreef 9, Amsterdam, the Netherlands.
Hanneke W M van LaarhovenCancer Centre Amsterdam, Cancer Treatment and Quality of Life, Amsterdam, the Netherlands.
Suzanne S GisbertzDepartment of Surgery, Amsterdam UMC, Location University of Amsterdam, Meibergdreef 9, Amsterdam, the Netherlands.
Sjoerd M LagardeDepartment of Surgery, Division of Surgical Oncology and Gastrointestinal Surgery, Erasmus Medical Centre Cancer Institute, Rotterdam, the Netherlands.
Nadia Haj MohammadDepartment of Medical Oncology, University Medical Centre Utrecht, Utrecht University, Utrecht, the Netherlands.
Peter S N van RossumCancer Centre Amsterdam, Cancer Treatment and Quality of Life, Amsterdam, the Netherlands.
Rob H A VerhoevenDepartment of Medical Oncology, Amsterdam UMC, Location University of Amsterdam, Amsterdam, the Netherlands.
Mark I van Berge HenegouwenDepartment of Surgery, Amsterdam UMC, Location University of Amsterdam, Meibergdreef 9, Amsterdam, the Netherlands.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: In the Netherlands, all inhabitants are required to have health insurance that covers standard medical care. While this regulated system aims to ensure equal access, recent evidence suggests that socioeconomic status (SES) disparities still exist. This study investigates SES-related differences in treatment and survival among patients with gastric or oesophageal cancer. Methods: This nationwide population-based study included gastroesophageal cancer patients diagnosed in 2015-2022. Patients were stratified into three SES-groups using median disposable household income per postal code area, an additional stratification was performed by histological subtype. Multivariable logistic regression was used to assess the likelihood of receiving specific treatments for different tumour types. Age-standardized relative survival was calculated as the ratio of observed survival to expected survival based on age, sex, calendar year, and median household income group in the general population. Findings: In total, 30,184 gastroesophageal cancer patients were categorized. In curable gastric cancer, patients with middle income had a significantly higher likelihood of receiving surgery compared to low income (OR 1.48 (95% CI 1.21-1.80), p < 0.001). For oesophageal cancer, both middle- (OR 1.17 (95% CI 1.05-1.30), p < 0.001) and high-income patients (OR 1.27 (95% CI 1.13-1.43), p < 0.001) were more likely to undergo surgery than those with low income. In palliative settings, middle- and high-income patients were also more likely to receive systemic therapy, in oesophageal cancer (OR 1.38 (95% CI 1.21-1.57), p < 0.001; OR 1.53 (95% CI 1.34-1.74), p < 0.001) and in gastric for high income (OR 1.27 (95% CI 1.05-1.55), p = 0.014). Relative survival analyses further demonstrated that middle- and high-income groups consistently had higher median, and 5-year survival compared to the low-income group. Interpretation: Despite universal health insurance, socioeconomic disparities in treatment and survival of gastroesophageal cancer patients persist in the Netherlands, reflecting not inequitable access but broader life-course health disparities that influence treatment fitness and outcomes. These findings highlight the need to address broader social and systemic determinants to improve equity in cancer care, in the Netherlands and globally. Funding: This study received no funding.

Indexed as

Gastric cancerOesophageal cancerOutcomesSocioeconomic statusTreatment

Identifiers

PMID41939011
PMCPMC13050078

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.